Corcept Therapeutics (CORT) Projected to Post Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) will likely be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Corcept Therapeutics to post earnings of $0.22 per share and revenue of $223.7790 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:00 PM ET.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. The company had revenue of $194.43 million during the quarter, compared to analysts’ expectations of $199.40 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 EPS. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $72.56 on Tuesday. The firm has a 50-day moving average of $76.25 and a two-hundred day moving average of $73.06. The stock has a market cap of $7.65 billion, a P/E ratio of 64.21 and a beta of 0.46. Corcept Therapeutics has a 1-year low of $42.01 and a 1-year high of $117.33.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $89.94, for a total transaction of $1,798,800.00. Following the completion of the sale, the insider owned 5,287 shares of the company’s stock, valued at $475,512.78. This represents a 79.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $85.06, for a total transaction of $1,701,200.00. Following the sale, the insider directly owned 7,904 shares of the company’s stock, valued at approximately $672,314.24. This represents a 71.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 292,451 shares of company stock worth $21,850,930. 20.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. grew its position in Corcept Therapeutics by 58.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 419,183 shares of the biotechnology company’s stock worth $30,768,000 after purchasing an additional 154,602 shares during the last quarter. Public Sector Pension Investment Board grew its position in Corcept Therapeutics by 8.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 321,768 shares of the biotechnology company’s stock worth $23,618,000 after purchasing an additional 26,027 shares during the last quarter. HRT Financial LP bought a new position in Corcept Therapeutics in the 2nd quarter worth about $14,753,000. Raymond James Financial Inc. grew its position in Corcept Therapeutics by 34.8% in the 2nd quarter. Raymond James Financial Inc. now owns 105,026 shares of the biotechnology company’s stock worth $7,709,000 after purchasing an additional 27,112 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in Corcept Therapeutics in the 2nd quarter worth about $7,059,000. Institutional investors own 93.61% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CORT. HC Wainwright restated a “buy” rating and issued a $145.00 target price on shares of Corcept Therapeutics in a research note on Monday, October 20th. Canaccord Genuity Group restated a “buy” rating and issued a $140.00 target price on shares of Corcept Therapeutics in a research note on Thursday, September 25th. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Finally, Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 1st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.